ASO Author Reflections: Importance of Preoperative Prediction of Survival in Resectable Pancreatic Ductal Adenocarcinoma

PASTMultidisciplinary treatment is crucial to prolong the survival of patients with pancreatic ductal adenocarcinoma (PDAC).Adjuvant chemotherapy has been highly established; however, the efficacy of neoadjuvant therapy for resectable PDAC remains controversial. 1,2The Prep-02/ JSAP-05 trial revealed the survival benefits of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable PDAC. 3 Conversely, effect of neoadjuvant therapy could differ according to the disease progression, 4 and optimal candidates of neoadjuvant therapy for resectable PDAC have not been well determined.Survival prediction upon diagnosis may help determine the treatment strategy for resectable PDAC.To date, previous studies have revealed several clinical factors that are associated with patient's survival.However, no single preoperative marker is sufficient to accurately predict postoperative survival for resectable PDAC.DISCLOSURE There are no conflicts of interest.